CMMB News and Press, Chemomab Therapeutics Ltd. From 05/05/25

SPRING Trial Data Presented at Digestive Disease Week ® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Prog...

2025-04-28 11:31:02 ET Chemomab Therapeutics (NASDAQ: CMMB ) unveiled new clinical results that they will present at the EASL 2025 Annual Congress on May 7-10 , providing additional support for its lead drug candidate, nebokitug (CM-101), as a potential treatment for primary scl...

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment fo...

TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd ., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the t...

David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial in PSC,...

Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improvements across key bio...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative ...

Air France-KLM ADR (AFLYY) is expected to report $0.02 for Q4 2024 Viracta Therapeutics Inc. (VIRX) is expected to report for Q4 2024 BJ's Wholesale Club Holdings Inc. (BJ) is expected to report $0.89 for Q4 2025 Deutsche Lufthansa AG ADR - Level I (DLAKY) is expected to report $0.22 ...

─ Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC) ─ ─ Achieved Alignment with FDA on Clear and Efficie...

Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC No Liver Biopsies or Additional Confirmatory Studies Required—...